Skip to main content

Advertisement

SpringerLink
Log in

Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

The purpose of this study was to determine if the functional single nucleotide polymorphisms of rs6259 C(-1019)G in the promoter region, which regulates serotonin 5-HT1A receptor transcription, affects the ability of antipsychotic drugs to improve attention in patients with schizophrenia.

Methods

Subjects were neuroleptic-free and meeting DSM-IV-TR criteria for schizophrenia. Psychopathology and attention were evaluated with the Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms (SANS) at baseline and 3 months after treatment with atypical antipsychotic drugs (AAPDs). DNA was extracted from peripheral blood following standard procedures. Genotyping was performed with HS-Taq assay (LaboPass™).

Results

Data were available from 30 subjects (male/female=19/11), in which 17 had the CC genotype, three had the GG genotype, and 10 were heterozygous. The 3-month treatment with AAPDs was associated with significant improvements in positive and negative symptoms, but not attention as measured by SANS-Attention subscale in the entire subject group. There were no significant differences in the degree of improvements of SAPS and SANS scores between the CC genotype group and the (C/G plus G/G) combined group. On the other hand, improvement of attention was significantly greater for the former group compared to the latter group (P<0.016), suggesting a detrimental influence of the G-allele.

Conclusion

These results provide additional support to the role of 5-HT1A receptors in some of the cognitive disturbances of schizophrenia. Further studies with a larger number of subjects are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the “right stuff”? Schizophr Bull. 2000;26:119–136.

    PubMed  CAS  Google Scholar 

  2. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res. 2000;45:175–184.

    Article  PubMed  CAS  Google Scholar 

  3. Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2007;95:158–168.

    Article  PubMed  Google Scholar 

  4. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther. 2000;295:853–861.

    PubMed  CAS  Google Scholar 

  5. Bantick RA, Deakin JF, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol. 2001;15:37–46.

    Article  PubMed  CAS  Google Scholar 

  6. Meltzer HY, Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res. 2008;195:98–102.

    Article  PubMed  CAS  Google Scholar 

  7. Sumiyoshi T, Bubenikova-Valesova V, Horacek J, Bert B. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Adv Ther. 2008;25:1037–1056.

    Article  PubMed  CAS  Google Scholar 

  8. Lesch KP, Gutknecht L. Focus on The 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics. Int J Neuropsychopharmacol. 2004;7:381–385.

    Article  PubMed  CAS  Google Scholar 

  9. Drago A, Ronchi DD, Serretti A. 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Int J Neuropsychopharmacol. 2008;11:701–721.

    Article  PubMed  CAS  Google Scholar 

  10. Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 1991;48:355–363.

    Article  PubMed  CAS  Google Scholar 

  11. Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 1996;708:209–214.

    Article  PubMed  CAS  Google Scholar 

  12. Kasper S, Tauscher J, Willeit M, et al. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette’s disorder—implications for psychopharmacology. World J Biol Psychiatry. 2002;3:133–146.

    Article  PubMed  Google Scholar 

  13. Tauscher J, Kapur S, Verhoeff NP, et al. Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry. 2002;59:514–520.

    Article  PubMed  CAS  Google Scholar 

  14. Frankle WG, Lombardo I, Kegeles LS, et al. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology (Berl). 2006;189:155–164.

    Article  CAS  Google Scholar 

  15. Lee MA, Meltzer HY. 5-HT(1A) receptor dysfunction in female patients with schizophrenia. Biol Psychiatry. 2001;50:758–766.

    Article  PubMed  CAS  Google Scholar 

  16. Sumiyoshi T, Meltzer HY. Serotonin1A receptors in memory function. Am J Psychiatry. 2004;161:1505.

    Article  PubMed  Google Scholar 

  17. Borg J. Molecular imaging of the 5-HT(1A) receptor in relation to human cognition. Behav Brain Res. 2008;195:103–111.

    Article  PubMed  CAS  Google Scholar 

  18. Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry. 2001;158:1722–1725.

    Article  PubMed  CAS  Google Scholar 

  19. Sumiyoshi T, Matsui M, Yamashita I, et al. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol. 2000;20:386–388.

    Article  PubMed  CAS  Google Scholar 

  20. Harvey PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev. 2009;19:324–335.

    Article  PubMed  Google Scholar 

  21. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry. 2002;159:1593–1595.

    Article  PubMed  Google Scholar 

  22. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry. 2006;163:1826–1829.

    Article  PubMed  Google Scholar 

  23. Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z. Pharmacogenetics of treatment in firstepisode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol. 2005;15:143–151.

    Article  PubMed  CAS  Google Scholar 

  24. Richtand NM, Welge JA, Logue AD, Keck PE, Jr., Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacol. 2007;32:1715–1726.

    Article  CAS  Google Scholar 

  25. Wang L, Fang C, Zhang A, et al. The —1019 C/G polymorphism of the 5-HT1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol. 2008;22:904–909.

    Article  PubMed  CAS  Google Scholar 

  26. Huang YY, Battistuzzi C, Oquendo MA, et al. Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol. 2004;7:441–451.

    Article  PubMed  CAS  Google Scholar 

  27. Kishi T, Tsunoka T, Ikeda M, et al. Serotonin1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. Neuropharmacol. 2010;58:452–456.

    Article  CAS  Google Scholar 

  28. Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol. 2004;7:453–460.

    Article  PubMed  CAS  Google Scholar 

  29. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol. 2004;7:501–506.

    Article  PubMed  CAS  Google Scholar 

  30. Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006;6:27–33.

    Article  PubMed  CAS  Google Scholar 

  31. Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ. Association study of two serotonin1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol. 2006;16:498–503.

    Article  PubMed  CAS  Google Scholar 

  32. Baune BT, Hohoff C, Roehrs T, Deckert J, Arolt V, Domschke K. Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression? Neurosci Lett. 2008;436:111–115.

    Article  PubMed  CAS  Google Scholar 

  33. Chung YC, Li Z, Dai J, Meltzer HY, Ichikawa J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res. 2004;1023:54–63.

    Article  PubMed  CAS  Google Scholar 

  34. Sato M, Ago Y, Koda K, et al. Role of postsynaptic serotonin1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex. Eur J Pharmacol. 2007;559:155–160.

    Article  PubMed  CAS  Google Scholar 

  35. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O’Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5- HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76:1521–1531.

    Article  PubMed  CAS  Google Scholar 

  36. Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci. 2005;25:10831–10843.

    Article  PubMed  CAS  Google Scholar 

  37. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (Text Revision). Washington DC: APA; 2000.

    Google Scholar 

  38. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. New York: New York State Psychiatric Institute; 1997.

    Google Scholar 

  39. Higuchi Y, Sumiyoshi T, Kawasaki Y, Matsui M, Arai H, Kurachi M. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: A LORETA analysis of P300. Schizophr Res. 2008;101:320–330.

    Article  PubMed  Google Scholar 

  40. Sumiyoshi T, Higuchi Y, Itoh T, et al. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLORETA. Psychiatry Res Neuroimag 2009;172:180–183.

    Article  CAS  Google Scholar 

  41. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa; 1983.

    Google Scholar 

  42. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1983.

    Google Scholar 

  43. Parsey RV, Oquendo MA, Ogden RT, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006;59:106–113.

    Article  PubMed  CAS  Google Scholar 

  44. Erdmann J, Shimron-Abarbanell D, Rietschel M, et al. Systematic screening for mutations in the human serotonin-2A receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet. 1996;97:614–619.

    Article  PubMed  CAS  Google Scholar 

  45. Sumiyoshi T. A possible dose-side effect relationship of antipsychotic drugs: Relevance to cognitive function in schizophrenia. Expert Rev Clin Pharmacol. 2008;1:791–802.

    Article  CAS  Google Scholar 

  46. Sumiyoshi T, Matsui M, Yamashita I, et al. The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Biol Psychiatry. 2001;49:861–868.

    Article  PubMed  CAS  Google Scholar 

  47. Yoshino T, Nishijima K, Shioda K, Yui K, Katoh S. Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medical prefrontal cortex. Neurosci Lett. 2004;24:16–21.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, 2630 Sugitani, Toyama, 930-0194, Japan

    Tomiki Sumiyoshi, Masahiko Tsunoda, Yuko Higuchi, Toru Itoh, Tomonori Seo, Hiroko Itoh, Michio Suzuki & Masayoshi Kurachi

  2. Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, Tokyo, Japan

    Tomiki Sumiyoshi, Michio Suzuki & Masayoshi Kurachi

Authors
  1. Tomiki Sumiyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiko Tsunoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuko Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toru Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomonori Seo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroko Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michio Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masayoshi Kurachi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomiki Sumiyoshi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sumiyoshi, T., Tsunoda, M., Higuchi, Y. et al. Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia. Adv Therapy 27, 307–313 (2010). https://doi.org/10.1007/s12325-010-0035-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0035-4

Keywords

Search

Navigation